# A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease

> **NCT02285088** · PHASE1 · COMPLETED · sponsor: **Global Blood Therapeutics** · enrollment: 133 (actual)

## Conditions studied

- Healthy Subjects
- Sickle Cell Disease

## Interventions

- **DRUG:** GBT440
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02285088
- **Lead sponsor:** Global Blood Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-03
- **Final completion:** 2017-05
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2018-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02285088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02285088, "A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT02285088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*